Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TransMedics reports stellar Q4 earnings, eyes growth amid operational challenges

TransMedics Group Inc delivered strong financial performance in Q4 2022, driven by robust revenue growth and strategic investments in infrastructure.
While facing margin pressure and operational challenges, the company's focus on innovation and expansion positions it well for future growth and market leadership.
With a clear roadmap for 2023 and a solid cash position, TransMedics is poised to navigate challenges, capitalize on opportunities, and drive sustainable value creation.

Transmedics reports stellar Q1 results, anticipates growth challenges ahead

Transmedics Group Inc (TMDX) delivered strong financial performance in Q1 2023, driven by the success of the TransMedics NOP and consistent growth in liver and heart cases. Despite facing operational challenges and increased expenses, the company remains optimistic about its growth prospects and revenue guidance for 2023. Strategic focus on product availability and infrastructure expansion bodes well for future success.

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The organ transplant specialist posted disappointing results in its third-quarter report.

Why TransMedics Stock Plunged in October

NEW YORK, NY / ACCESSWIRE / November 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

Levi & Korsinsky Announces an Investigation on Behalf of TransMedics Group, Inc. (TMDX) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

TMDX ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your TransMedics Group, Inc. investment

NEW YORK, NY / ACCESSWIRE / November 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

TransMedics Group, Inc. Being Investigated on Behalf of TransMedics Group, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by TransMedics Group, Inc. (TMDX)

TransMedics quickly became the leader in liver, heart, and lung transplants, but its third-quarter earnings left the market worried. Here's why I believe its pullback in share price is an opportunity.

1 Top Growth Stock Down 50% to Buy After Its Recent Pullback

SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-transmedics-group-inc-investigation-tmdx.html   You can also contact attorneys J.C.

TMDX INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

TransMedics Group, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - TMDX

Micron Technology

Remitly Global

These three stocks have dropped over 30% from their 52-week highs. At the same time, analysts expect strong revenue and earnings growth for them soon.

3 Stocks Well Below 52-Week Highs With Strong Growth Projections

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

TransMedics Group, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - TMDX

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving TransMedics Group, Inc. (NASDAQ: TMDX) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the TransMedics investigation or if you are a TransMedics investor who suffered a loss and would like to.

TMDX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into TransMedics Group, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

TransMedics (TMDX) Reports Q3 Earnings: What Key Metrics Have to Say

TMDX which was outperforming the S&P500 by 6x in August, is now only generating half the returns of the benchmark on a YTD basis. The Q3 event appears to have spooked investors and we dive in to cover some of the key themes. We close with some thoughts on how investors should approach TMDX now.

TransMedics: Maintaining A Neutral Stance After A Difficult Q3

TransMedics Group, Inc. faces significant challenges due to aircraft maintenance issues and rising aviation costs, leading to a 42% stock price drop and a HOLD rating. Revenue shortfall is attributed to a national decline in transplant volumes and reduced service component charges, impacting margins and overall financial performance. The company's aviation operations are struggling with unscheduled maintenance, reducing operational aircraft and causing missed revenue opportunities.

TransMedics: Every Hero Becomes A Bore At Last

TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.

TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of TransMedics Group, Inc. ("TransMedics Group, Inc.") (NASDAQ:TMDX) concerning possible violations of federal securities laws. On October 28, 2024, TransMedics reported disappointing financial results for the third quarter of 2024, missing analyst expectations on both the top and bottom lines.

Did TransMedics Group, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - TMDX

TransMedics shares fell 25% pre-market after a disappointing Q3 report, missing revenue and EPS estimates, with management failing to manage expectations. Despite the poor quarter, the long-term opportunity remains large, and a good Q4 could significantly boost shares. Management's poor guidance and failure to prepare investors for the downturn were major issues, but the potential for growth still exists.

TransMedics: Mistakes Have Been Made, Here's My Updated Outlook

TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday.

These Analysts Cut Their Forecasts On TransMedics Group Following Weak Results

Is this the buy-the-dip opportunity investors have been waiting for?

TransMedics Stock Crashes After Earnings Disappointment. Time to Load Up the Boat?

Crocs

D.R. Horton

U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Tuesday.

TransMedics Group Posts Weak Results, Joins Harmonic, Crocs, D.R. Horton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- DiCello Levitt LLP announces that it is investigating whether TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ:TMDX) complied with federal securities laws. The Firm's investigation focuses on whether the Company violated the federal securities laws, issued false and/or misleading statements, and/or failed to disclose information required to be disclosed to investors.

INVESTIGATION ALERT (NASDAQ:TMDX): DiCello Levitt LLP Is Investigating Investor Claims Against TransMedics Group, Inc. and Encourages TMDX Investors with Losses to Contact the Firm

TransMedics Group, Inc. (NASDAQ:TMDX ) Q3 2024 Earnings Conference Call October 28, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Stephen Gordon - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan William Plovanic - Canaccord Joshua Jennings - TD Cowen Ryan Daniels - William Blair Matthew O'Brien - Piper Sandler Suraj Kalia - Oppenheimer & Company David Rescott - Baird Mike Matson - Needham & Company Operator Good afternoon and welcome to the TransMedics Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript

TransMedics (TMDX) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.28 per share. This compares to loss of $0.12 per share a year ago.

TransMedics (TMDX) Q3 Earnings and Revenues Miss Estimates

Boot Barn Hlds

F5 Networks

With earnings season in full swing, big winners and losers abound. TransMedics and F5 were notable movers Monday night.

TransMedics, F5 Lead Big After-Hours Earnings Winners, Losers

ANDOVER, Mass. , Oct. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter ended September 30, 2024.

News for Transmedics Group Inc Stock (TMDX)